A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): Study protocol for a randomized controlled trial

Trials

Volumn 15, Issue 1, 2014, Pages

  Robinson, Sian ^a   Zincuk, Aleksander ^a   Larsen, Ulla L ^a   Ekstrøm, Claus ^b   Toft, Palle ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Acute kidney injury; Anti factor Xa activity; Continuous renal replacement therapy; Critically ill patients; Deep vein thrombosis; Enoxaparin; Neutrophil gelatinase associated lipocalin; Pulmonary embolism; Renal recovery; Thromboprophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; ACUTE PHASE PROTEIN; ANTICOAGULANT AGENT; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BLEEDING; BLOOD CLOT; CLINICAL PROTOCOL; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DENMARK; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT COMPLIANCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS PREVENTION; URINE VOLUME; VENOUS THROMBOEMBOLISM; VENTILATOR; ACUTE KIDNEY INJURY; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; CRITICAL ILLNESS; METHODOLOGY; RENAL REPLACEMENT THERAPY; URINE;

ACUTE KIDNEY INJURY; ACUTE-PHASE PROTEINS; ADULT; ANTICOAGULANTS; CRITICAL ILLNESS; DOUBLE-BLIND METHOD; ENOXAPARIN; HEMORRHAGE; HUMANS; LIPOCALINS; PROTO-ONCOGENE PROTEINS; RENAL REPLACEMENT THERAPY; RESEARCH DESIGN; VENOUS THROMBOEMBOLISM;

EID: 84902041902     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-226     Document Type: Article

References (22)

1. Cruz DN, De CM, Garzotto F, Perazella MA, Lentini P, Corradi V, Piccinni P, Ronco C. Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population. Intensive Care Med 2010, 36:444-451. 10.1007/s00134-009-1711-1, 2820221, 19956925.
2. Bagshaw SM, Bennett M, Haase M, Haase-Fielitz A, Egi M, Morimatsu H, D'amico G, Goldsmith D, Devarajan P, Bellomo R. Plasma and urine neutrophil gelatinase-associated lipocalin in septic versus non-septic acute kidney injury in critical illness. Intensive Care Med 2010, 36:452-461. 10.1007/s00134-009-1724-9, 19956924.
3. Kumpers P, Hafer C, Lukasz A, Lichtinghagen R, Brand K, Fliser D, Faulhaber Walter R, Kielstein JT. Serum neutrophil gelatinase-associated lipocalin at inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury. Crit Care 2010, 14:R9. 10.1186/cc8861, 2875521, 20122150.
4. de Geus HR, Bakker J, Lesaffre EM, le Noble JL. Neutrophil gelatinase-associated lipocalin at ICU admission predicts for acute kidney injury in adult patients. Am J Respir Crit Care Med 2011, 183:907-914. 10.1164/rccm.200908-1214OC, 20935115.
5. Fraisse F, Holzapfel L, Couland JM, Simonneau G, Bedock B, Feissel M, Herbecq P, Pordes R, Poussel JF, Roux L. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD: the Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 2000, 161:1109-1114. 10.1164/ajrccm.161.4.9807025, 10764298.
6. Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE, Zytaruk N, Crowther M, Geerts W, Cooper DJ, Vallance S, Qushmaq I, Rocha M, Berwanger O, Vlahakis NE. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 2011, 364:1305-1314.
7. Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH. Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 2001, 161:1268-1279. 10.1001/archinte.161.10.1268, 11371254.
8. Ocak G, Vossen CY, Rotmans JI, Lijfering WM, Rosendaal FR, Parlevliet KJ, Krediet RT, Boeschoten EW, Dekker FW, Verduijn M. Venous and arterial thrombosis in dialysis patients. Thromb Haemost 2011, 106:1046-1052. 10.1160/TH11-06-0422, 22012181.
9. Cook DJ, Douketis J, Arnold D, Crowther MA. Bleeding and venous thromboembolism in the critically ill with emphasis on patients with renal insufficiency. Curr Opin Pulm Med 2009, 15:455-462. 10.1097/MCP.0b013e32832ea4dd, 19617833.
10. Cook DJ, Crowther MA. Thromboprophylaxis in the intensive care unit: focus on medical-surgical patients. Crit Care Med 2010, 38:S76-S82.
11. Arnold DM, Donahoe L, Clarke FJ, Tkaczyk AJ, Heels-Ansdell D, Zytaruk N, Cook R, Webert KE, McDonald E, Cook DJ. Bleeding during critical illness: a prospective cohort study using a new measurement tool. Clin Invest Med 2007, 30:E93-E102.
12. Chan CM, Shorr AF. Venous thromboembolic disease in the intensive care unit. Semin Respir Crit Care Med 2010, 31:39-46. 10.1055/s-0029-1246283, 20101546.
13. Minet C, Lugosi M, Savoye PY, Menez C, Ruckly S, Bonadona A, Schwebel C, Hamidfar-Roy R, Dumanoir P, Ara-Somohano C, Ferretti GR, Timsit JF. Pulmonary embolism in mechanically ventilated patients requiring computed tomography: prevalence, risk factors, and outcome. Crit Care Med 2012, 40:3202-3208. 10.1097/CCM.0b013e318265e461, 23164766.
14. Shorr AF, Williams MD. Venous thromboembolism in critically ill patients: observations from a randomized trial in sepsis. Thromb Haemost 2009, 101:139-144.
15. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008, 133:141S-159S. 10.1378/chest.08-0689, 18574264.
16. Ho KM, Chavan S, Pilcher D. Omission of early thromboprophylaxis and mortality in critically ill patients: a multicenter registry study. Chest 2011, 140:1436-1446. 10.1378/chest.11-1444, 21940768.
17. Robinson S, Zincuk A, Larsen UL, Ekstrom C, Nybo M, Rasmussen B, Toft P. A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: double-blinded, randomized controlled trial. Crit Care 2013, 17:R75. 10.1186/cc12684, 4057520, 23601744.
18. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006, 4:759-765. 10.1111/j.1538-7836.2006.01787.x, 16634744.
19. Wells PS, Anderson DR, Bormanis J, Guy F, Mitchell M, Gray L, Clement C, Robinson KS, Lewandowski B. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997, 350:1795-1798. 10.1016/S0140-6736(97)08140-3, 9428249.
20. Wells PS, Anderson DR, Rodger M, Ginsberg JS, Kearon C, Gent M, Turpie AG, Bormanis J, Weitz J, Chamberlain M, Bowie D, Barnes D, Hirsh J. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000, 83:416-420.
21. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Control Clin Trials 1984, 5:348-361. 10.1016/S0197-2456(84)80014-8, 6518769.
22. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R, . Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013, 39:165-228. 10.1007/s00134-012-2769-8, 23361625, Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup.